Since tamoxifen also possesses partial ER agonistic activity, the steroidal drug fulvestrant was developed as a selective estrogen receptor degrader with activity against ER-positive tamoxifen-resistant breast cancer[102]. Here, ESR1 is linked to breast carcinoma.